Olinvacimab, TTAC-0001

Indications: Solid tumors

Olinvacimab is an anti-angiogenic antibody that neutralizes the VEGF/VEGFR2 pathway, thus inhibiting tumor growth and metastasis.

Mechanism of action / Target

Olinvacimab is a direct VEGFR2 antagonist that block the binding of all VEGFR ligands such as VEGF-A, VEGF-C and VEGF-D to VEGFR2. To gain nutrients and oxygen needed for growth, tumor cells release these VEGF ligands which promote angiogenesis (a formation of new blood vessels) that will enhance tumor blood supply. Binding of olinvacimab to VEGFR2 will result in the inhibition of VEGF-mediated tumor angiogenesis.


PharmAbcine has three ongoing global clinical trials involving Olinvacimab. Of the three ongoing global trials, two are combo studies with MSD’s pembrolizumab in mTNBC and rGBM, and one is a mono study in Avastin non-responding rGBM. Both phase Ib combination trials are expected to be completed by the end of 2020, and a phase II olinvacimab and pembrolizumab combination trial in mTNBC is in preparation.

     2F, Research Building 2, 70,

     Yuseong-daero 1689 beon-gil,
     Yuseong-gu, Daejeon, 34047, Republic of Korea

     HQ +82-42-863-2017 

     R&D Center +82-42-861-2017

     Investor Relations +70-4294-6097 

     FAX +82-42-863-2080 

     COPYRIGHT BY PharmAbcine Inc.